Share on StockTwits

Infinity Pharmaceuticals (NASDAQ:INFI) released its earnings data on Tuesday. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.06, American Banking and Market News reports. During the same quarter in the previous year, the company posted ($0.68) earnings per share. The company’s revenue for the quarter was up NaN% on a year-over-year basis.

Infinity Pharmaceuticals (NASDAQ:INFI) opened at 9.14 on Tuesday. Infinity Pharmaceuticals has a 1-year low of $8.40 and a 1-year high of $23.36. The stock has a 50-day moving average of $11.0 and a 200-day moving average of $11.60. The company’s market cap is $443.7 million.

INFI has been the subject of a number of recent research reports. Analysts at Morgan Stanley initiated coverage on shares of Infinity Pharmaceuticals in a research note on Wednesday, June 25th. They set an “overweight” rating and a $17.00 price target on the stock. On the ratings front, analysts at Wedbush cut their price target on shares of Infinity Pharmaceuticals from $10.00 to $9.00 in a research note on Friday, May 9th. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Infinity Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $20.00 price target on the stock, down previously from $25.00. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $17.11.

Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.